Back to UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

KYMRKYMR
21 quarters

Position history for UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in KYMERA THERAPEUTICS INC

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds 736,866 shares of KYMR (KYMERA THERAPEUTICS INC), worth $84.5M as of 2026-Q2. The position was decreased (-15.9% shares). KYMR represents 0.0% of UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's portfolio.

Current Value

$84.5M

Current Shares

736,866

Total Value Change

+$70.8M

Total Shares Change

+454,827

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
736,866
-15.9%
$84.5M0.0%$114.67
0
2026-Q1
Decreased
875,872
-4.0%
$73M0.0%$86.35
0
2025-Q4
Increased
912,498
+5.6%
$71M0.0%$78.12
31
2025-Q3
Increased
863,762
+5.5%
$48.9M0.0%$58.50
31
2025-Q2
Decreased
818,927
-8.6%
$35.7M0.0%$44.12
0
2025-Q1
Increased
896,404
+121.5%
$24.5M0.0%$29.62
46
2024-Q4
Decreased
404,667
-5.6%
$16.3M0.0%$39.32
0
2024-Q3
Decreased
428,529
-1.2%
$20.3M0.0%$48.69
0
2024-Q2
Increased
433,573
+141.0%
$12.9M0.0%$29.85
45
2024-Q1
Increased
179,938
+1.9%
$7.2M0.0%$40.20
28
2023-Q4
Decreased
176,500
-7.0%
$4.5M0.0%$25.46
0
2023-Q3
Increased
189,733
+7.5%
$2.6M0.0%$13.90
28
2023-Q2
Unchanged
176,528
0.0%
$5.2M0.0%$22.40
0
2023-Q1
Decreased
176,528
-1.7%
$5.2M0.0%$28.27
0
2022-Q4
Increased
179,567
+7.2%
$4.5M0.0%$24.96
29
2022-Q3
Decreased
167,545
-13.8%
$3.6M0.0%$22.07
0
2022-Q2
Decreased
194,324
-54.8%
$3.8M0.0%$20.29
0
2022-Q1
Increased
430,243
+61.7%
$18.2M0.0%$41.51
41
2021-Q4
Decreased
266,051
-0.1%
$16.9M0.0%$62.98
0
2021-Q3
Decreased
266,289
-5.6%
$15.6M0.0%$58.45
0
2021-Q2
New
282,039
-
$13.7M0.0%$42.64
39

Other major holders of KYMR: FMR LLC, BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used